Pfizer
NEWS
This week Pfizer notified the Bay Area-based company of its intent to terminate its five-year-old oncology collaboration.
Giuseppe Ciaramella, formerly chief scientific officer of Moderna Therapeutics’ Valera unit, has left for an unidentified stealth-mode biotech startup.
Pfizer is fighting to preserve Lyrica’s use as the preferred physician’s treatment for nerve pain in the U.K.
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) announced a string of approvals, as well as a couple rejections.
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions.
Kite, a Gilead Company, has inked a worldwide collaboration deal with Sangamo Therapeutics to develop oncology therapeutics.
Despite the recent dismal news regarding Alzheimer’s drug development, the U.S. Food and Drug Administration (FDA) recently proposed new guidelines for developing drugs for the disease.
Detailed results from the JAVELIN Lung 200 trial will be submitted for presentation at an upcoming medical congress.
Late-stage data shows the use of Pfizer’s prostate cancer drug Xtandi plus ADT significantly reduced the risk of developing metastases or death by 71 percent.
JOBS
IN THE PRESS